

First Hit

Previous Doc

Next Doc

Go to Doc#

End of Result Set

Generale Collection | Public

L4: Entry 35 of 35

File: DWPI

Feb 13, 1996

DERWENT-ACC-NO: 1996-157020

DERWENT-WEEK: 199616

COPYRIGHT 2005 DERWENT INFORMATION LTD

TITLE: Drugs for treatment of corneal damage - obtd. by hydrolysis of lactoferrin.

PATENT-ASSIGNEE: MORINAGA MILK IND CO LTD (MORG), SENJU SEIYAKU KK (SENP)

PRIORITY-DATA: 1994JP-0181212 (August 2, 1994)



PATENT-FAMILY:

PUB-NO JP 08040925 PUB-DATE

LANGUAGE

PAGES MAIN-IPC

February 13, 1996

010 F

A61K038/00

APPLICATION-DATA:

PUB-NO

APPL-DATE

APPL-NO

DESCRIPTOR

JP 08040925A

August 2, 1994

1994JP-0181212

INT-CL (IPC): A61 K 9/06; A61 K 9/08; A61 K 38/00; A61 K 38/16

ABSTRACTED-PUB-NO: JP 08040925A

BASIC-ABSTRACT:

Drugs for treatment of corneal damage (specifically: Sjogren's syndrome, chemically corrosive corneal ulcer) contain a peptide obtd. by hydrolysis of <u>lactoferrin</u>, or its derivs. or salts or their mixt.

The eye-lotion, e.g. may be prepd. with a buffer (e.g. borate, citrate, tartrate, phosphate, acetate; pH 4-6), isotonic agent (e.g. glucose, mannitol, NaCl), preservative (e.g. benzalkonium chloride), thickener (e.g. hydroxyethylcellulose), stabiliser, anti-oxidant, pH-regulator, chelating agent, absorption promoter. The ointment may be made with a base, e.g. vaseline, paraffin, PEG, CMC.

USE - The drugs accelerate the growth of corneal epithelial cell and useful in treatment of xerokeratoconjunctivitis (a condition of Sjogren's syndrome) or in improvement of ocular diseases caused by hypo-lacrimation, e.g. xerophthalmia, foreign body sensation, burning sensation, conjunctival congestion, keratitis filamentosa, ectocorneal erosion. Drugs may be applied as 0.00001-5.0 w/v%, pref. 0.0001-1 w/v%, eye-lotion or ointment, or orally or parenterally as powder, granules, tablets, capsules or injection. One to several drops of the eye-lotion 1-4 times a day. Eye lotion contains e.g. 1g peptide, 0.9g NaCl, 0.1g NaOCOMe and a proper amt. MeCOOH were made to 100ml (pH 5.0) with sterilised water.



In a test with MRL mice having Sjogren's syndrome, the ectocorneal opacity was improved by application of 0.2% peptide/eye lotion 4 times a daY for one month.

ABSTRACTED-PUB-NO: JP 08040925A

EQUIVALENT-ABSTRACTS:

CHOSEN-DRAWING: Dwg.0/1

DERWENT-CLASS: B04

CPI-CODES: B04-N02; B14-N03;

Previous Doc Next Doc Go to Doc#